SEC Form 4 · accession 0001193125-26-297817
Kymera Therapeutics, Inc. · KYMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nello Mainolfi
Officer — Chief Executive Officer · Director
Period of report
Jul 7, 2026
Accepted (ET)
Jul 7, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001815442
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 7, 2026 | M | 50,000 | $2.08 | A | 716,568 | D | |
| Common Stock | Jul 7, 2026 | S | 50,000 | $119.00 | D | 666,568 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.08 | Jul 7, 2026 | M | 45,559 | D | — | Nov 13, 2029 | Common Stock | 45,559 | 90,000 | D |
| Stock Option (Right to Buy)F2 | $2.08 | Jul 7, 2026 | M | 4,441 | D | — | Nov 13, 2029 | Common Stock | 4,441 | 14,284 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.
- F2The shares underlying this stock option are fully vested and exercisable.